A nationwide voluntary recall covers four lots of Cetirizine Hydrochloride Tablets USP, 5 mg, distributed by Rising Pharma Holdings. FDA records identify NDC 16571-401-10 in 100-count bottles and lots GY825029, GY825030, GY825031 and GY825032, all with an October 2028 expiration date. The notice does not cover every cetirizine product.
Timeline
July 18, 2026 — The company dated its voluntary nationwide recall announcement. July 20 — FDA published the announcement and separately listed the recall in its drug-recall index. August 3 — U.S. search interest rose, making the exact lot identifiers more useful than the broad phrase ‘cetirizine recall.’
Cetirizine is a common allergy medicine, so a broad search phrase can create unnecessary alarm. The actionable information is narrow: strength, NDC, bottle count, lot number and expiration date. Consumers can compare those details with the label instead of assuming that all generic or brand-name cetirizine is affected.
The notice affects four named lots rather than the whole cetirizine market. Watch the FDA recall record for scope changes, additional lot information or a termination notice—not social-media claims that omit the product identifiers.
What happened?
Unique Pharmaceutical Laboratories recalled the four consumer-level lots after a pharmacy technician reported red dots and discoloration on tablets. The company says testing identified potential cross-contamination with ranitidine and that it had not received reports of adverse events when the announcement was posted.
Why it matters
Cetirizine is a common allergy medicine, so a broad search phrase can create unnecessary alarm. The actionable information is narrow: strength, NDC, bottle count, lot number and expiration date. Consumers can compare those details with the label instead of assuming that all generic or brand-name cetirizine is affected.
Background
A nationwide voluntary recall covers four lots of Cetirizine Hydrochloride Tablets USP, 5 mg, distributed by Rising Pharma Holdings. FDA records identify NDC 16571-401-10 in 100-count bottles and lots GY825029, GY825030, GY825031 and GY825032, all with an October 2028 expiration date. The notice does not cover every cetirizine product.
What each side says
The recalling company says the action is voluntary and precautionary after testing found potential ranitidine cross-contamination. FDA separately lists the recall in its drug-recall index and publishes the company announcement as a public service; the agency notes that posting an announcement is not an endorsement of either the product or the company.
What happens next
Check the bottle for Cetirizine Hydrochloride Tablets USP 5 mg, NDC 16571-401-10, a 100-count package and one of the four listed lots. FDA's notice directs consumers with questions to the recall contact and advises contacting a physician or healthcare provider about problems that may be related to the product. Do not substitute a trend post for individualized medical advice.
Nivegu analysis
The recall is real, but the viral shorthand is imprecise. FDA's record describes a potential manufacturing cross-contamination issue in four specific lots. It does not say that every cetirizine tablet is contaminated, and no adverse events had been reported to the company at publication time.
Different viewpoints
Patients and pharmacies that retain the original bottle can identify the affected product quickly. A lot-specific recall also lets unaffected products remain available.
People who no longer have the labeled container may be unable to verify the lot themselves. Patients who stop an allergy medicine without asking a pharmacist or healthcare professional may also lose needed symptom control.
What we know
The central claims in this briefing are tied to the sources below. Analysis and inference are labeled separately; uncertainty stays visible.
✓ SOURCE-BACKEDWhat are you still wondering?
Answers will use this briefing and its cited sources.Sources
Read the evidence, not just our conclusion.
01FDA — Unique Pharmaceutical Laboratories cetirizine recall announcement↗02FDA — Drug recalls index↗03FDA — Pediatric safety communications↗04Express Scripts — Cetirizine recall notice↗05Google Trends — United States↗Questions, answered.
What is the short version?
A nationwide voluntary recall covers four lots of Cetirizine Hydrochloride Tablets USP, 5 mg, distributed by Rising Pharma Holdings. FDA records identify NDC 16571-401-10 in 100-count bottles and lots GY825029, GY825030, GY825031 and GY825032, all with an October 2028 expiration date. The notice does not cover every cetirizine product.
Why does this matter now?
Cetirizine is a common allergy medicine, so a broad search phrase can create unnecessary alarm. The actionable information is narrow: strength, NDC, bottle count, lot number and expiration date. Consumers can compare those details with the label instead of assuming that all generic or brand-name cetirizine is affected.
What should readers watch next?
The notice affects four named lots rather than the whole cetirizine market. Watch the FDA recall record for scope changes, additional lot information or a termination notice—not social-media claims that omit the product identifiers.
